
Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases
Novo Nordisk is expanding its prospects in obesity and other metabolic disorders by securing rights to an early-clinical engineered peptide whose effects comes from activating three receptors — the same three targets hit by a next-generation weight drug in …